PeerCurrent.com|Stay current with the people and research shaping what comes next.

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Researcher

Zuojuan Xiang

Central South University

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials Reviews Guidelines

Latest

Everything in the corpus, newest first.

AUG 18, 2026 · JOURNAL ARTICLE

Cost-effectiveness analysis of disitamab vedotin plus toripalimab versus chemotherapy as first-line treatment for HER2-expressing advanced urothelial cancer

Human Vaccines & Immunotherapeutics

A modeled cost-effectiveness analysis from a single healthcare system showing the intervention meets the threshold, but dependent on assumptions about treatment duration and subsequent costs that proved sensitive in scenario testing.

PromisingZuojuan Xiang Bladder and Urothelial Cancer Treatments Renal Cell Carcinoma Treatment

Reported

ICER (base case)$18,448.74 per QALY

Willingness-to-pay threshold$40,334 per QALY

ICER (scenario analysis)$66,303.62 per QALY

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support